Zacks Initiates Coverage of bioAffinity With Neutral Recommendation

Zacks Investment Research has recently initiated coverage of bioAffinity Technologies, Inc. (BIAF) , assigning a "Neutral" recommendation to the company's shares. This assessment comes amid a mixed outlook for the company, which has been making notable strides in the lung cancer diagnostics space despite industry challenges.BIAF, headquartered in San Antonio, TX, develops non-invasive diagnostics for detecting early-stage lung cancer and other lung diseases. The company is also advancing research into poten ...